Inflammaging is a chronic, low-grade, sterile inflammation that develops with aging, representing one of the most significant biological hallmarks of organismal aging. This page provides detailed information about its molecular mechanisms, relationship to neurodegenerative diseases, and therapeutic implications. The term, coined by Dr. Claudio Franceschi in 2000, combines "inflammation" with "aging" to describe the persistent, subclinical inflammatory state that characterizes the aging process across species[1].
Inflammaging differs fundamentally from acute inflammation in several key aspects: it is chronic (lasting years to decades), sterile (occurring in the absence of pathogens), low-grade (involving modest elevations in inflammatory mediators), and systemic (affecting multiple organ systems simultaneously). This persistent inflammatory state is now recognized as a major driver of age-related diseases, including neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis[2].
Inflammaging is characterized by elevated pro-inflammatory cytokines, chemokines, and acute-phase proteins in the absence of acute infection. The inflammatory milieu of aging includes consistently elevated levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β), among other mediators. These elevated inflammatory markers correlate strongly with mortality risk, cognitive decline, and functional impairment in elderly populations[3].
The sources of inflammaging are multifactorial and include: (1) accumulated cellular senescence and the senescence-associated secretory phenotype (SASP); (2) chronic viral infections (particularly Epstein-Barr virus and cytomegalovirus); (3) gut microbiota dysbiosis and increased intestinal permeability ("leaky gut"); (4) mitochondrial dysfunction and cell-free mitochondrial DNA release; (5) accumulated nuclear and mitochondrial DNA damage; (6) decreased autophagy and impaired protein homeostasis; and (7) adipose tissue inflammation and visceral adiposity[4].
In the brain, inflammaging contributes to cognitive decline, synaptic dysfunction, and neuronal death through multiple interconnected pathways. The blood-brain barrier (BBB) becomes more permeable with age, allowing peripheral inflammatory signals to enter the central nervous system.同时, brain resident immune cells—particularly microglia—undergo phenotypic changes that amplify inflammatory responses[5].
Cellular senescence is a state of irreversible cell cycle arrest that occurs in response to various stresses including telomere erosion, DNA damage, oncogenic stress, and mitochondrial dysfunction. Senescent cells accumulate in tissues with age, and their persistence is thought to contribute significantly to organismal aging through the SASP—a complex secretome that includes pro-inflammatory factors[6].
The SASP comprises hundreds of proteins and bioactive molecules:
Pro-inflammatory cytokines:
Chemokines:
Growth factors and remodeling factors:
The SASP creates a pro-inflammatory microenvironment that propagates inflammation to neighboring cells through paracrine signaling, a process termed "paracrine senescence." Additionally, senescent cells escape immune surveillance through upregulation of anti-apoptotic pathways, allowing them to persist and secrete their inflammatory cargo indefinitely[7].
The NLRP3 (NLR family pyrin domain containing 3) inflammasome is a key driver of inflammaging and has been implicated in numerous neurodegenerative diseases. This cytosolic protein complex senses danger signals including:
Upon activation, NLRP3 recruits the adaptor protein ASC and pro-caspase-1, forming the inflammasome complex. This leads to caspase-1 activation, which then cleaves pro-IL-1β and pro-IL-18 to their mature, secreted forms. The resulting inflammatory cascade propagates throughout the tissue microenvironment[8].
In the brain, NLRP3 inflammasome activation in microglia drives chronic IL-1β release, which impairs amyloid clearance while promoting tau pathology spread. The inflammasome also contributes to neuroinflammation in Parkinson's disease through activation by α-synuclein oligomers[9].
Brain microglia become primed (sensitized) with aging, lowering their activation threshold and fundamentally altering their response to challenges. This age-related microglial transformation represents a critical nexus between systemic inflammaging and brain inflammation[10].
Microglial priming is characterized by:
Primed microglia exhibit enhanced pro-inflammatory responses to secondary stimuli, a phenomenon called "microglial priming." This creates a feedforward loop where age-related challenges trigger exaggerated neuroinflammation. The concept of "priming" explains why peripheral infections (like pneumonia or urinary tract infections) can trigger acute cognitive decline in older adults—a phenomenon termed delirium[11].
The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway serves as the master transcriptional regulator of inflammaging. This transcription factor controls the expression of hundreds of inflammatory genes, including cytokines, chemokines, adhesion molecules, and enzymes involved in oxidative stress[12].
NF-κB is activated by:
The canonical NF-κB pathway involves IκB kinase (IKK) phosphorylation of IκBα, releasing p50/p65 dimers to translocate to the nucleus. Chronic NF-κB activation in aging tissues creates a self-perpetuating inflammatory loop that drives tissue dysfunction and contributes to neurodegeneration.
Telomere shortening with age triggers the DNA damage response (DDR), which activates NF-κB and promotes inflammation. Critically short telomeres become recognized as DNA damage, triggering p53 and NF-κB pathways that drive SASP expression. Leukocyte telomere length correlates with inflammatory marker levels and cognitive decline in elderly populations[13].
In Alzheimer's disease (AD), the most common neurodegenerative disorder, inflammaging interacts with the two hallmark pathologies—amyloid-beta (Aβ) plaques and neurofibrillary tau tangles—in a complex bidirectional relationship[14].
Aβ oligomers activate the NLRP3 inflammasome in microglia through multiple mechanisms:
This activation drives chronic IL-1β release that impairs amyloid clearance while promoting tau pathology spread. The inflammatory response to Aβ also includes TNF-α, IL-6, and chemokine production, creating a neurotoxic microenvironment that contributes to synaptic dysfunction and neuronal loss[15].
Pathological tau species (hyperphosphorylated tau, oligomers, tangles) activate microglia through multiple receptors:
The resulting neuroinflammation creates a self-perpetuating cycle where inflammatory kinases (CDK5, GSK-3β) promote tau phosphorylation, while tau pathology further activates microglia. This bidirectional relationship between tau and inflammation accelerates disease progression[16].
Key inflammatory markers elevated in AD include:
The APOE ε4 allele, the strongest genetic risk factor for sporadic AD, modulates microglial responses to Aβ and influences inflammatory pathways[17].
Parkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Inflammaging contributes to PD pathogenesis through multiple interconnected mechanisms[18].
The substantia nigra is particularly vulnerable to inflammatory damage due to several factors:
Chronic activation of substantia nigra microglia leads to progressive dopaminergic neuron loss. Postmortem studies show increased HLA-DR positive microglia in the substantia nigra of PD patients, and PET imaging using TSPO ligands confirms microglial activation in living PD patients[19].
α-Synuclein, the protein that forms Lewy bodies in PD, activates microglia through:
The prion-like spreading of α-synuclein pathology may be facilitated by inflammatory-mediated changes in cellular transport and degradation pathways[20].
Systemic inflammaging increases blood-brain barrier (BBB) permeability, allowing peripheral immune cells and inflammatory mediators to enter the brain. This "inflammaging-gut-brain axis" connects peripheral inflammation to central nervous system pathology:
Age-related gut dysbiosis and intestinal inflammation may initiate or accelerate PD pathology through vagal nerve signaling. The gut microbiome in PD patients shows altered composition, and germ-free animals are protected from α-synuclein pathology. This connection provides a mechanistic basis for the Braak hypothesis, which proposes that PD pathology initiates in the enteric nervous system and propagates retrogradely through the vagus nerve to the brain[21].
Amyotrophic lateral sclerosis (ALS) shows particularly robust inflammatory components, with neuroinflammation present at all disease stages and across multiple brain regions[22].
Elevated pro-inflammatory cytokines in cerebrospinal fluid include:
These mediators create a hostile microenvironment that accelerates motor neuron degeneration. The interplay between motor neuron vulnerability and inflammatory cascades represents a therapeutic target being actively investigated[23].
ALS genes influence inflammatory pathways:
Frontotemporal dementia (FTD) shows significant neuroinflammation, particularly in the frontal and temporal cortices. Microglial activation correlates with disease severity and progression, and inflammatory biomarkers (IL-6, TNF-α) are elevated in FTD patient CSF[24].
Huntington's disease (HD) features prominent neuroinflammation starting early in disease course. Mutant huntingtin protein activates microglia and astrocytes, and peripheral inflammatory markers predict disease progression. The inflammatory response contributes to striatal neuron loss and cognitive decline[25].
While primarily an autoimmune demyelinating disease, multiple sclerosis (MS) shows features of inflammaging, with chronic inflammation continuing despite immunosuppressive therapies. Age-related changes in immune function affect disease progression and treatment response[26].
Drugs that selectively eliminate senescent cells have shown promise in preclinical models of neurodegeneration:
| Drug/Combination | Target | Status |
|---|---|---|
| Dasatinib + Quercetin | Multiple senescent cell types | Clinical trials for AD, PD |
| Fisetin | Senescent neurons and astrocytes | Preclinical |
| Navitoclax | BCL-2 family anti-apoptotic proteins | Preclinical |
| Rapamycin | mTOR; reduces SASP | Approved for other indications |
| 17-DMAG | HSP90; reduces SASP | Preclinical |
The Dasatinib + Quercetin (D+Q) combination has shown cognitive benefits in animal models and is being evaluated in clinical trials for Alzheimer's disease[27].
| Approach | Mechanism | Challenge |
|---|---|---|
| NLRP3 inhibitors (MCC950, dapansutrile) | Block inflammasome activation | Brain penetration |
| IL-1β antibodies (canakinumab) | Neutralize IL-1β | Peripheral only |
| TNF-α inhibitors (etanercept, infliximab) | Block TNF signaling | BBB crossing |
| Minocycline | Microglial inhibition | Efficacy limited in trials |
| Brandedicumab | Anti-IL-6R antibody | Being tested in AD |
Exercise: Regular physical activity reduces systemic inflammation through multiple mechanisms, including decreased visceral fat, improved gut microbiome, reduced SASP, and increased anti-inflammatory cytokines (IL-10, TGF-β)[28].
Caloric restriction: Reduces inflammatory markers and extends healthspan through metabolic remodeling, including increased autophagy and reduced mTOR signaling.
Diet: Mediterranean diet and omega-3 fatty acids demonstrate anti-inflammatory effects through:
Sleep: Adequate sleep (7-8 hours) reduces inflammatory markers, while sleep disruption increases IL-6 and CRP levels.
Stress management: Chronic stress increases inflammation; mindfulness and stress reduction reduce inflammatory biomarkers.
Clinical and research use of inflammaging biomarkers includes:
Systemic inflammatory markers:
Cellular senescence markers:
Brain-specific markers:
The field of inflammaging in neurodegeneration continues to evolve, with several key research directions emerging:
Single-cell RNA sequencing and spatial transcriptomics are revolutionizing our understanding of inflammaging by:
Establishing causality between inflammaging and neurodegeneration remains challenging. Key approaches include:
Translating basic science insights into clinical benefits requires:
Integrating genomics, transcriptomics, proteomics, and metabolomics data will help identify:
Franceschi et al. 'Inflammaging: an evolutionary perspective on immunosenescence (Nature Reviews Immunology, 2000)'. 2000. ↩︎
Inflammaging and brain aging (Nature Reviews Neuroscience, 2020). 2020. ↩︎
Puzianowska-Kuznicka et al. Inflammaging and successful aging (Geroscience, 2022). 2022. ↩︎
Fulop et al. Cellular Senescence in Age-Related Disorders (Nature Reviews Disease Primers, 2020). 2020. ↩︎
Microglial priming in aging and disease (Glia, 2019). 2019. ↩︎
The Senescence-Associated Secretory Phenotype (Cell, 2018). 2018. ↩︎
Coppe et al. Senescence and the SASP (Cell Cycle, 2010). 2010. ↩︎
NLRP3 inflammasome in neurodegeneration (Trends in Neurosciences, 2021). 2021. ↩︎
NLRP3 and Alzheimer's disease (Acta Neuropathologica, 2020). 2020. ↩︎
Microglial aging in the CNS (Journal of Neuroinflammation, 2023). 2023. ↩︎
[ Microglial priming and delirium (Lancet Neurology, 2021)](https://doi.org/10.1016/S1474-4422(21). 2021. ↩︎
NF-κB in inflammation and immunity (Cold Spring Harbor Perspectives in Biology, 2021). 2021. ↩︎
Telomere length and inflammation (Aging Cell, 2022). 2022. ↩︎
Amyloid and inflammation in AD (Nature Reviews Neuroscience, 2021). 2021. ↩︎
NLRP3 inflammasome in AD (Acta Neuropathologica, 2020). 2020. ↩︎
Tau and neuroinflammation (Nature Reviews Neuroscience, 2021). 2021. ↩︎
Inflammation in Parkinson's disease (Nature Reviews Neurology, 2019). 2019. ↩︎
Alpha-synuclein and NLRP3 (Movement Disorders, 2022). 2022. ↩︎
Gut-brain axis in PD (Nature Reviews Neurology, 2020). 2020. ↩︎
ALS genetics and inflammation (Nature Reviews Neurology, 2023). 2023. ↩︎
[ Multiple sclerosis and inflammaging (Lancet Neurology, 2023)](https://doi.org/10.1016/S1474-4422(23). 2023. ↩︎
Senolytics in neurodegeneration (Nature Medicine, 2023). 2023. ↩︎
Exercise and inflammation (Brain, Behavior, and Immunity, 2021). 2021. ↩︎